Axsome Therapeutics (AXSM) Equity Ratio (2015 - 2026)

Axsome Therapeutics has disclosed Equity Ratio across 12 years of filings, most recently posting 0.08 for Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.08, down 14.21% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.08 (down 14.21% YoY), and the FY2025 annual result was 0.13, up 27.63% from the prior year.
• Equity Ratio came in at 0.08 for Q1 2026 at Axsome Therapeutics, down from 0.13 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.46 in Q3 2022 to a low of 0.08 in Q1 2026.
• The 5-year median for Equity Ratio is 0.17 (2022), against an average of 0.22.
• Across the five-year window, Equity Ratio tumbled 83.12% in 2022 and soared 441.51% in 2023, its largest moves.
• Axsome Therapeutics' Equity Ratio stood at 0.33 in 2022, then decreased by 1.77% to 0.32 in 2023, then tumbled by 69.11% to 0.1 in 2024, then rose by 27.63% to 0.13 in 2025, then plunged by 40.24% to 0.08 in 2026.
• The last three Equity Ratio figures came in at 0.08 (Q1 2026), 0.13 (Q4 2025), and 0.11 (Q3 2025), per Business Quant data.